• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

New Antibiotic Discovery Shows Promise Against Highly Drug-Resistant Bacteria

January 5, 2024 by Deborah Bloomfield

An antibiotic belonging to an entirely new class of drugs has been discovered, and it has already shown promise against one of the greatest bacterial threats to human health. Clinical trials have begun, and if they go well, it could mean the addition of a much-needed new tool to our antimicrobial arsenal.

The antibiotic, identified by Claudia Zampaloni, Patrizio Mattei, Konrad Bleicher, and colleagues, has been named zosurabalpin, and the excitement comes from experiments in the lab and in mice that show it can target a highly drug-resistant strain of a bacterium called Acinetobacter baumannii.

Advertisement

The carbapenem-resistant strain of A. baumannii, nicknamed CRAB, has been identified as a priority 1 critical pathogen by the World Health Organization. The bug is impervious to nearly all antibiotics, and resistant individuals in a population can share their protective genes easily with the other bacteria around them.

CRAB is of particular concern in healthcare settings. People most at risk of infection include those with indwelling medical devices like catheters, those who are in intensive care or who have to stay in hospital for a long time, and those recovering from surgical wounds. When someone does get infected with CRAB it’s extremely difficult to treat, which is why new drugs are so desperately needed.

A. baumannii is a Gram-negative bacterium. Other notable examples of this class of bacteria include Pseudomonas aeruginosa and everyone’s favourite model organism, good old Escherichia coli. They’re notoriously difficult to kill, thanks to their outer membrane composed of lipopolysaccharide (LPS). Many antibiotics can’t get through this protective shield – so, if you want to get at a Gram-negative, you really need to be targeting the LPS.

Zosurabalpin does just that. As detailed in a second published paper, it stops LPS from reaching the outer membrane in the first place by messing with the transport mechanisms that move the LPS to the correct place in the bacterial cell.

Advertisement

“Surprisingly, this new class of antibiotics binds both to the transport complex as well as the LPS itself, preventing its transport to the outer membrane,” explained Kenneth Bradley, Global Head, Infectious Disease Discovery at Roche Pharma Research & Early Development, in a statement.

“Consequently, the LPS remains trapped in the inner membrane complex. Without the ability to transport LPS the bacteria die.”

This means the new drug can get around the defenses that CRAB has developed to other medications, but the scientists caution that more research is needed to investigate whether the wily microbes might one day be able to develop resistance to zosurabalpin too.

This discovery could potentially lead to novel treatments for other Gram-negative pathogens, which also target the LPS transport system. As just one example, P. aeruginosa led to an estimated 32,600 hospital-acquired infections in 2017, and it too is becoming more difficult to treat. In a Nature News and Views article accompanying the recent studies, Morgan K. Gugger and Paul J. Hergenrother pointed out that it’s been over 50 years since the US Food and Drug Administration approved a new antibiotic for use against harmful Gram-negative bacteria.

Advertisement

Clinical trials for zosurabalpin are already underway. The road from lab experiments to clinical use of a new drug can be very long, but there’s still some hope that this discovery could represent a turning point in the fight against one of the greatest challenges facing humankind today.

The two studies are published in Nature, here and here.

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. Paris ramps up security as jihadist attacks trial starts
  2. Cricket-‘Western bloc’ has let Pakistan down, board chief says
  3. Ancient Bison Found In Permafrost Is So Well Preserved Scientists Want To Clone It
  4. Where Inside Us Do We Feel Love?

Source Link: New Antibiotic Discovery Shows Promise Against Highly Drug-Resistant Bacteria

Filed Under: News

Primary Sidebar

  • Unethical Experiments: When Scientists Really Should Have Stopped What They Were Doing Immediately
  • The First Humans Were Hunted By Leopards And Weren’t The Apex Predators We Thought They Were
  • Earth’s Passage Through The Galaxy Might Be Written In Its Rocks
  • What Is An Einstein Cross – And Why Is The Latest One Such A Unique Find?
  • If We Found Life On Mars, What Would That Mean For The Fermi Paradox And The Great Filter?
  • The Longest Living Mammals Are Giants That Live Up To 200 Years In The Icy Arctic
  • Entirely New Virus Detected In Bat Urine, And It’s Only The 4th Of Its Kind Ever Isolated
  • The First Ever Full Asteroid History: From Its Doomed Discovery To Collecting Its Meteorites
  • World’s Oldest Pachycephalosaur Fossil Pushes Back These Dinosaurs’ Emergence By 15 Million Years
  • The Hole In The Ozone Layer Is Healing And On Track For Full Recovery In The 21st Century, Thanks To Science
  • First Sweet Potato Genome Reveals They’re Hybrids With A Puzzling Past And 6 Sets Of Chromosomes
  • Why Is The Top Of Canada So Sparsely Populated? Meet The “Canadian Shield”
  • Humans Are In The Middle Of “A Great Evolutionary Transition”, New Paper Claims
  • Why Do Some Toilets Have Two Flush Buttons?
  • 130-Year-Old Butter Additive Discovered In Danish Basement Contains Bacteria From The 1890s
  • Prehistoric Humans Made Necklaces From Marine Mollusk Fossils 20,000 Years Ago
  • Zond 5: In 1968 Two Soviet Steppe Tortoises Beat Humans To Orbiting Around The Moon
  • Why Cats Adapted This Defense Mechanism From Snakes
  • Mother Orca Seen Carrying Dead Calf Once Again On Washington Coast
  • A Busy Spider Season Is Brewing: Why This Fall Could See A Boom Of Arachnid Activity
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version